Recent 8-K filings for LNTH

• May 7, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Lantheus Q1 revenue $377.3M (+1.2% YoY); GAAP EPS $1.80, adjusted EPS $1.46

  Worldwide revenue $377.3M (+1.2%); GAAP diluted EPS $1.80 (+76.5%), adjusted diluted EPS $1.46 (-4.6%).

• May 1, 2026, 7:59 PM ET other material materiality 0.60 neutral item 3.03item 5.03item 5.02item 5.07item 9.01 ◈ Governance Changes

  Lantheus shareholders approve board declassification and amended equity plan with 2M additional shares

  Certificate of Amendment filed to declassify Board of Directors over three years; removal with/without cause after declassification.

• November 12, 2025, 6:59 PM ET leadership materiality 0.65 neutral item 5.02

  Lantheus CEO Brian Markison to retire Dec 31, 2025; consulting deal through Mar 31, 2026

  CEO Brian Markison retiring effective Dec 31, 2025; enters consulting agreement from Jan 1 to Mar 31, 2026.

• November 6, 2025, 6:59 PM ET earnings materiality 0.85 neutral item 2.02item 5.02item 7.01item 9.01

  Lantheus Q3 revenue $384M (+1.4% YoY), adj. EPS $1.27; CEO Markison to retire, Heino interim CEO

  GAAP net income $27.8M ($0.41 fully diluted EPS); adjusted EPS $1.27, down 25.3% YoY.

• August 6, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 8.01item 9.01

  Lantheus Q2 rev $378M, adj EPS $1.57; cuts FY25 guidance; FDA NDA acceptance; $400M buyback

  Q2 revenue $378.0M (-4.1% YoY); GAAP EPS $1.12; adjusted EPS $1.57.

• July 22, 2025, 7:59 PM ET M&A materiality 0.75 positive item 2.01item 7.01item 9.01 ◈ M&A Transactions

  Lantheus closes $350M acquisition of Life Molecular Imaging; names Dr. Dinkelborg as Head of R&D

  Completed acquisition of Life Molecular for $350M cash after adjustments, gaining Alzheimer's PET agent Neuraceq.

• May 7, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Lantheus Q1 adj EPS $1.53 (-9.5% YoY); cuts FY25 adj EPS guidance to $6.60-$6.70 from $7.00-$7.20

  Q1 revenue $372.8M (+0.8% YoY); GAAP EPS $1.02 vs $1.87; adj EPS $1.53 vs $1.69.

• April 1, 2025, 7:59 PM ET M&A materiality 0.75 positive item 2.01item 7.01item 9.01 ◈ M&A Transactions

  Lantheus closes $275M acquisition of Evergreen Theragnostics; adds OCTEVY and CDMO capabilities

  Closed acquisition of Evergreen Theragnostics for $275M cash upfront ($250M + $25M milestone achieved pre-close).

• February 26, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Lantheus Q4 revenue $391M (+10.5%); GAAP EPS $(0.17), adj. EPS $1.59; FY25 guide $1.55B-$1.61B

  Q4 revenue $391.1M (+10.5% YoY); PYLARIFY $266M (+15.7%), DEFINITY $86.2M (+17.9%).

• January 28, 2025, 6:59 PM ET M&A materiality 0.85 positive item 1.01item 2.02item 7.01item 9.01

  Lantheus to acquire Evergreen Theragnostics for $250M upfront plus up to $752.5M in milestones

  Upfront cash consideration $250M; potential milestone payments up to $752.5M based on OCTEVY and pipeline products.

• January 13, 2025, 6:59 PM ET M&A materiality 0.90 positive item 1.01item 7.01item 9.01

  Lantheus to Acquire Life Molecular Imaging for $350M Upfront with Potential $400M Earnout

  Upfront cash payment of $350M for Life Molecular Imaging, with up to $400M in potential earnout and milestone payments.

• December 23, 2024, 6:59 PM ET debt materiality 0.72 positive item 1.01item 2.03item 9.01

  Lantheus expands revolving credit facility to $750M, extends maturity to Dec 2029

  Revolving line increased from $350M to $750M; can request another $350M.

• November 20, 2024, 6:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Lantheus authorizes $250M share repurchase program over next 12 months

  Board authorized up to $250M in common stock repurchases within one year.

• November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Lantheus Q3 revenue up 18.4% to $378.7M; adjusted EPS $1.70 beats prior year

  GAAP net income $131.1M ($1.79 diluted EPS) vs $132.0M ($1.88) in Q3 2023.

• September 25, 2024, 7:59 PM ET other material materiality 0.65 neutral item 7.01

  Lantheus to release SPLASH trial data in Oct 2024 after 75% OS events reached

  Expects to release Phase 3 SPLASH data in October 2024 for 177Lu-PNT2002 in PSMA-expressing mCRPC.

• July 31, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Lantheus Q2 revenue up 22.5% to $394.1M, adjusted EPS $1.80; lowers FY 2024 adjusted EPS guidance to $6.60-$6.70

  Revenue $394.1M (+22.5% YoY), driven by PYLARIFY sales $273.3M (+29.8%) and DEFINITY $78.1M (+10.7%).

• June 27, 2024, 7:59 PM ET M&A materiality 0.68 positive item 7.01item 9.01

  Lantheus acquires global rights to Life Molecular's GRPR-targeting radiotheranostic pair for $35M upfront

  Upfront payment $35M plus regulatory milestone payments and royalties.

• May 2, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Lantheus Q1 revenue $370M (+23% YoY), EPS $1.87; raises FY2024 guidance

  Q1 revenue $370M (+23% YoY); PYLARIFY sales $258.9M (+32.4%), DEFINITY $76.6M (+11.2%)

• February 22, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Lantheus Q4 2023 rev $354M (+34.5%), adj EPS $1.75; FY2024 guidance raised

  Q4 2023 revenue $354M (+34.5% YoY), including $15M RELISTOR milestone; FY2023 revenue $1.3B (+38.6% YoY).

• January 26, 2024, 6:59 PM ET litigation materiality 0.60 neutral item 7.01

  Lantheus confirms patent infringement lawsuit by Novartis over generic Lutetium Lu 177 Dotatate ANDA

  Lawsuit filed by Advanced Accelerator Applications (Novartis entities) in U.S. District Court for Delaware against Lantheus and its subsidiary.

• January 23, 2024, 6:59 PM ET leadership materiality 0.80 positive item 5.02item 9.01 ◈ executive_change ×5

  Lantheus CEO Heino retires March 1; Markison named CEO; FY23 revenue $1.295-1.297B, up 38-39%

  Mary Anne Heino to retire as CEO effective March 1, 2024; becomes Chair of the Board.

• January 9, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Lantheus pre-announces FY2023 revenue ~$1.296B, beating guidance; PYLARIFY up 62%

  Worldwide revenue expected $1.295-1.297B, up 38-39% YoY, above prior guidance of $1.255-1.270B.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.68 · Most common event earnings

13 positive 1 negative 17 neutral

source · LNTH on sec.gov